Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.
Julien GrynblatCharles KhouriAlex HlavatyXavier JaisLaurent SavaleMarie-Camille ChaumaisMithum KularatneMitja JevnikarAthénaïs BouclyFabrice AntignyFrédéric PerrosGérald SimonneauOlivier SitbonMarc HumbertI David Montaninull nullPublished in: The European respiratory journal (2024)
PIs may induce PAH in patients undergoing treatment, with carfilzomib emitting a stronger signal than bortezomib, and these patients should be monitored closely.
Keyphrases
- end stage renal disease
- newly diagnosed
- patients undergoing
- pulmonary hypertension
- ejection fraction
- chronic kidney disease
- prognostic factors
- multiple myeloma
- patient reported outcomes
- coronary artery
- pulmonary arterial hypertension
- pulmonary artery
- insulin resistance
- patient reported
- weight loss
- glycemic control